期刊文献+

COPD患者呼出气冷凝液中多项因子检测及与肺功能的相关性分析 被引量:2

Correlative analysis between EBC levels of IL-6,IL-8,hsCRP,TNF-α and pulmonary function in patients with COPD
下载PDF
导出
摘要 目的探讨健康对照组、COPD稳定期组和COPD急性加重组中hsCRP、TNF-α、IL-6、IL-8水平变化及与肺功能的相关性。方法纳入30例健康者、28例COPD稳定期患者和30例COPD急性加重期患者作为研究对象,测定EBC中hsCRP、TNF-α、IL-6、IL-8的浓度,以及与第1秒用力呼吸量占预计值的百分比的相关分析。结果 (1)COPD急性加重组中hsCRP、TNF-α、IL-6、IL-8水平高于COPD稳定期组,差异具有显著性(P<0.05)。(2)COPD稳定期组hsCRP、TNF-α、IL-6、IL-8水平均高于对照组,差异具有显著性(P<0.05)。(3)COPD急性加重组中TNF-α、IL-6、IL-8水平均与FEV1%呈负相关(P<0.05),而hsCRP与FEV1%则无明显相关性。结论 COPD气道炎症与hsCRP、TNF-α、IL-6、IL-8水平释放增多有关,检测EBC中hsCRP、TNF-α、IL-6、IL-8水平可作为判断COPD病情及预后的指标。 Objective To investigate the relationship between EBC levels of interleukin-6 (IL-6), interleu-kin-8 (IL-8), hsCRP, TNF-α and pulmonary function in patients with COPD. Methods The levels of hsCRP, TNF-α, IL-6 and IL-8 were detected from 30 cases of normal volunteers, 28 cases in stable period of COPD and 30 cases of acute exacerbation of COPD. FEV1% was correlated analyzed. Results (1) The levels of hsCRP, TNF-α, IL-6 and IL-8 in patients with AECOPD were significantly higher than those in stable period of COPD ( P〈0. 05 ) . (2) The levels of hsCRP, TNF-α, IL-6 and IL-8 in patients with stable period of COPD were significantly higher than those in normal volunteers (P〈0. 05). (3) The level of TNF-α, IL-6 and IL-8 in patients with AECOPD were negatively correlated with FEV1% (P〈0. 05). But the level of hsCRP had no relation with FEV1%. Conclusion The increased levels of hsCRP, TNF-α, IL-6 and IL-8 play certain role in acute exacerbation of COPD, which can be indicators in judging the prognosis of COPD.
出处 《临床肺科杂志》 2014年第11期1997-1999,共3页 Journal of Clinical Pulmonary Medicine
  • 相关文献

参考文献3

二级参考文献14

  • 1有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量:279
  • 2Pauwels R. Global initiative for chronic obstructive lung diseases (GOLD) : time to act[J]. Eur Respir J, 2001,18 (6) : 901-902.
  • 3Risby T H. Further discussion on breath condensate analysis [J]. Am J Respir Crit Care Med,2003,167(10). 1301-1302.
  • 4Kostikas K, Gaga M, Papatheodorou G,et al. Leukotriene B4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma[J]. Chest, 2005,127(5) : 1553-1559.
  • 5Montuschi P,Macagno F,Parente P, et al. Effects of cyclooxygenase inhibition on exhaled eicosanoids in patients with COPD[J]. Thorax, 2005,60 (10) : 827-833.
  • 6Kilfeather S. 5 lipoxygenase inhibitors for the treatment of COPD [J]. Chest, 2002,121 (5 Suppl ): 197S-200S.
  • 7Schumann C, Triantafilou K, Krueger S, et al. Mediators of inflammation[M]. New York:Hindawi Publishing Corporation, 2006 : 1-5.
  • 8GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
  • 9Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
  • 10Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012.

共引文献8291

同被引文献16

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部